Gino Kenny (Dublin Mid West, People Before Profit Alliance) | Oireachtas source

If the programme is not broadened in its conditions, I do not see it going anywhere for medical and commercial reasons. The Danish medical cannabis access programme has been open since 2018 and 2,500 patients have got medical cannabis products via prescription. Some of the conditions it is being prescribed for are not in the medical access programme here. One particular example of that is neuropathic pain. The evidence around the effect of cannabis on neuropathic pain is very good. Access programmes throughout the world allow cannabis for the treatment of chronic pain or neuropathic pain. Chronic pain is a very broad term. The omission of chronic pain in the initial report was very controversial. A whole host of people could benefit from medical cannabis, particularly for neuropathic pain.

See this speech in context